Emerging structural insights into biased GPCR signaling

Trends in Biochemical Sciences

Volumn 39, Issue 12, 2014, Pages 594-602

  Shukla, Arun K ^a   Singh, Garima ^a   Ghosh, Eshan ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

Author keywords

Biased agonism; Biased signaling; G protein coupled receptors (GPCRs); arrestin; 2 adrenergic receptor'

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR; VASOPRESSIN RECEPTOR; LIGAND;

CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; THERMOSTABILITY; X RAY CRYSTALLOGRAPHY; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; CHEMISTRY; METABOLISM;

ANIMALS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84919328202     PISSN: 09680004     EISSN: 13624326     Source Type: Journal    
DOI: 10.1016/j.tibs.2014.10.001     Document Type: Review

References (84)

1. Shukla A.K., et al. Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 2011, 36:457-469.
2. Benovic J.L. G-protein-coupled receptors signal victory. Cell 2012, 151:1148-1150.
3. Katritch V., et al. Structure-function of the G protein-coupled receptor superfamily. Annu. Rev. Pharmacol. Toxicol. 2013, 53:531-556.
4. Bockaert J., Pin J.P. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 18:1723-1729.
5. Ma P., Zemmel R. Value of novelty. Nat. Rev. Drug Discov. 2002, 1:571-572.
6. Gainetdinov R.R., et al. Desensitization of G protein-coupled receptors and neuronal functions. Annu. Rev. Neurosci. 2004, 27:107-144.
7. Lohse M.J., et al. G-protein-coupled receptor kinases. Kidney Int. 1996, 49:1047-1052.
8. Kang D.S., et al. Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking. Curr. Opin. Cell Biol. 2014, 27:63-71.
9. Lohse M.J., et al. beta-Arrestin: a protein that regulates beta-adrenergic receptor function. Science 1990, 248:1547-1550.
10. Gurevich V.V., Gurevich E.V. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 2006, 110:465-502.
11. Goodman O.B., et al. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature 1996, 383:447-450.
12. Reiter E., et al. Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu. Rev. Pharmacol. Toxicol. 2012, 52:179-197.
13. Luttrell L.M., et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 1999, 283:655-661.
14. Luttrell L.M., Miller W.E. Arrestins as regulators of kinases and phosphatases. Prog. Mol. Biol. Transl. Sci. 2013, 118:115-147.
15. Beaulieu J.M., et al. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122:261-273.
16. DeFea K.A., et al. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta-arrestin-dependent scaffolding complex. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:11086-11091.
17. DeFea K.A., et al. Beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 2000, 148:1267-1281.
18. McDonald P.H., et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000, 290:1574-1577.
19. DeWire S.M., et al. Beta-arrestin-mediated signaling regulates protein synthesis. J. Biol. Chem. 2008, 283:10611-10620.
20. Zoudilova M., et al. beta-Arrestins scaffold cofilin with chronophin to direct localized actin filament severing and membrane protrusions downstream of protease-activated receptor-2. J. Biol. Chem. 2010, 285:14318-14329.
21. Sun X., et al. Beta-arrestin 2 modulates resveratrol-induced apoptosis and regulation of Akt/GSK3ss pathways. Biochim. Biophys. Acta 2010, 1800:912-918.
22. Lin A., DeFea K.A. Beta-arrestin-kinase scaffolds: turn them on or turn them off?. Wiley Int. Rev. Syst. Biol. Med. 2013, 5:231-241.
23. DeFea K.A. Beta-arrestins as regulators of signal termination and transduction: how do they determine what to scaffold?. Cell. Signal. 2011, 23:621-629.
24. McGovern K.W., DeFea K.A. Molecular mechanisms underlying beta-arrestin-dependent chemotaxis and actin-cytoskeletal reorganization. Handb. Exp. Pharmacol. 2014, 219:341-359.
25. DeFea K.A. Arrestins in actin reorganization and cell migration. Prog. Mol. Biol. Transl. Sci. 2013, 118:205-222.
26. Xiao K., et al. Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15299-15304.
27. Kendall R.T., et al. The beta-arrestin pathway-selective type 1A angiotensin receptor (AT1A) agonist [Sar1,Ile4,Ile8] angiotensin II regulates a robust G protein-independent signaling network. J. Biol. Chem. 2011, 286:19880-19891.
28. Christensen G.L., et al. Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol. Cell. Proteomics 2010, 9:1540-1553.
29. Walters R.W., et al. Beta-arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J. Clin. Invest. 2009, 119:1312-1321.
30. Urs N.M., et al. A dopamine D1 receptor-dependent beta-arrestin signaling complex potentially regulates morphine-induced psychomotor activation but not reward in mice. Neuropsychopharmacology 2011, 36:551-558.
31. Wei H., et al. Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10782-10787.
32. Kenakin T., Christopoulos A. Measurements of ligand bias and functional affinity. Nat. Rev. Drug Discov. 2013, 12:483.
33. Kenakin T., Christopoulos A. Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat. Rev. Drug Discov. 2013, 12:205-216.
34. Luttrell L.M., Kenakin T.P. Refining efficacy: allosterism and bias in G protein-coupled receptor signaling. Methods Mol. Biol. 2011, 756:3-35.
35. Whalen E.J., et al. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
36. Allen J.A., et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18488-18493.
37. Frankowski K.J., et al. Discovery of small molecule kappa opioid receptor agonist and antagonist chemotypes through a HTS and hit refinement strategy. ACS Chem. Neurosci. 2012, 3:221-236.
38. Jarpe M.B., et al. [D-Arg1,D-Phe5,D-Trp7,9,Leu11] Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J. Biol. Chem. 1998, 273:3097-3104.
39. Kenakin T.P. Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors. J. Pharmacol. Exp. Ther. 1982, 223:416-423.
40. Kenakin T.P., Beek D. Relative efficacy of prenalterol and pirbuterol for beta-1 adrenoceptors: measurement of agonist affinity by alteration of receptor number. J. Pharmacol. Exp. Ther. 1984, 229:340-345.
41. Kenakin T.P., Morgan P.H. Theoretical effects of single and multiple transducer receptor coupling proteins on estimates of the relative potency of agonists. Mol. Pharmacol. 1989, 35:214-222.
42. Kenakin T.P. Seven transmembrane receptors as nature's prototype allosteric protein: de-emphasizing the geography of binding. Mol. Pharmacol. 2008, 74:541-543.
43. Shenoy S.K., et al. Beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor. J. Biol. Chem. 2006, 281:1261-1273.
44. Noma T., et al. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 2007, 117:2445-2458.
45. Woo A.Y., et al. Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. Mol. Pharmacol. 2009, 75:158-165.
46. Zimmerman B., et al. Differential beta-arrestin-dependent conformational signaling and cellular responses revealed by angiotensin analogs. Sci. Signal. 2012, 5:ra33.
47. Wisler J.W., et al. Recent developments in biased agonism. Curr. Opin. Cell Biol. 2014, 27:18-24.
48. Shonberg J., et al. Biased agonism at G protein-coupled receptors: the promise and the challenges: a medicinal chemistry perspective. Med. Res. Rev. 2014, 10.1002/med.21318.
49. Marti-Solano M., et al. Novel insights into biased agonism at G protein-coupled receptors and their potential for drug design. Curr. Pharm. Des. 2013, 19:5156-5166.
50. Luttrell L.M. Minireview: More than just a hammer: ligand 'bias' and pharmaceutical discovery. Mol. Endocrinol. 2014, 28:281-294.
51. Shukla A.K. Biasing GPCR signaling from inside. Sci. Signal. 2014, 7:pe3.
52. Reiter E., Lefkowitz R.J. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol. Metab. 2006, 17:159-165.
53. Weiss J.M., et al. The cubic ternary complex receptor-occupancy model. III. resurrecting efficacy. J. Theor. Biol. 1996, 181:381-397.
54. Kenakin T.P. New eyes to see texture in ligand efficacy. Nat. Methods 2005, 2:163-164.
55. Kenakin T.P. '7TM receptor allostery: putting numbers to shapeshifting proteins. Trends Pharmacol. Sci. 2009, 30:460-469.
56. Kahsai A.W., et al. Multiple ligand-specific conformations of the beta2-adrenergic receptor. Nat. Chem. Biol. 2011, 7:692-700.
57. Shukla A.K., et al. Distinct conformational changes in beta-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:9988-9993.
58. Nobles K.N., et al. Distinct phosphorylation sites on the beta(2)-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin. Sci. Signal. 2011, 4:ra51.
59. Drake M.T., et al. beta-arrestin-biased agonism at the beta2-adrenergic receptor. J. Biol. Chem. 2008, 283:5669-5676.
60. Liu J.J., et al. Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR. Science 2012, 335:1106-1110.
61. Wisler J.W., et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16657-16662.
62. Rasmussen S.G.F., et al. Crystal structure of the beta(2) adrenergic receptor-Gs protein complex. Nature 2011, 477:549-555.
63. Rasmussen S.G.F., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
64. Kirchberg K., et al. Conformational dynamics of helix 8 in the GPCR rhodopsin controls arrestin activation in the desensitization process. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18690-18695.
65. Gurevich V.V., Gurevich E.V. Structural determinants of arrestin functions. Prog. Mol. Biol. Transl. Sci. 2013, 118:57-92.
66. Shukla A.K., et al. Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature 2014, 512:218-222.
67. Rasmussen S.G., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469:175-180.
68. Rosenbaum D.M., et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011, 469:236-240.
69. Kim K.M., Caron M.G. Complementary roles of the DRY motif and C-terminus tail of GPCRS for G protein coupling and beta-arrestin interaction. Biochem. Biophys. Res. Commun. 2008, 366:42-47.
70. Rovati G.E., et al. The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol. Pharmacol. 2007, 71:959-964.
71. Bokoch M.P., et al. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463:108-112.
72. Nygaard R., et al. The dynamic process of beta(2)-adrenergic receptor activation. Cell 2013, 152:532-542.
73. Mary S., et al. Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:8304-8309.
74. Mary S., et al. How ligands and signalling proteins affect G-protein-coupled receptors' conformational landscape. Biochem. Soc. Trans. 2013, 41:144-147.
75. Rahmeh R., et al. Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:6733-6738.
76. Warne T., et al. Crystal structures of a stabilized beta1-adrenoceptor bound to the biased agonists bucindolol and carvedilol. Structure 2012, 20:841-849.
77. Warne T., et al. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature 2008, 454:486-491.
78. Wacker D., et al. Structural features for functional selectivity at serotonin receptors. Science 2013, 340:615-619.
79. Wang C., et al. Structural basis for molecular recognition at serotonin receptors. Science 2013, 340:610-614.
80. Shukla A.K., et al. Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature 2013, 497:137-141.
81. Bruning J.B., et al. Coupling of receptor conformation and ligand orientation determine graded activity. Nat. Chem. Biol. 2010, 6:837-843.
82. Darimont B.D., et al. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998, 12:3343-3356.
83. Burris T.P., et al. Nuclear receptors and their selective pharmacologic modulators. Pharmacol. Rev. 2013, 65:710-778.
84. Kojetin D.J., Burris T.P. Small molecule modulation of nuclear receptor conformational dynamics: implications for function and drug discovery. Mol. Pharmacol. 2013, 83:1-8.